LOXL2 and breast cancer: LOXL2 has similar biological activities in ECM remodeling as LOX, and its overexpression indicates poor prognosis in patients with colon and esophageal squamous cell carcinoma [40], as well as gastric cancer and breast cancer [41, 42].